

LISTE DE MÉDICAMENTS DANGEREUX - MARS 2024

SOUS-COMITÉ - LISTE DE MÉDICAMENTS DANGEREUX, COMMUNAUTÉ DE PRATIQUE
DU QUÉBEC POUR LA MANIPULATION SÉCURITAIRE DES MÉDICAMENTS DANGEREUX

Version du 13 mars 2024

*******Vous devez lire l'avis important avant de consulter la liste*******

Contexte

Conformément au Guide *Manipulation sécuritaire des médicaments dangereux* de l' Association paritaire pour la santé et la sécurité du travail du secteur affaires sociales (ASSTSAS), une liste locale des médicaments dangereux devrait être établie dans chaque installation où des médicaments dangereux sont manipulés (www.asstsas.qc.ca/gp65). La plus récente liste du NIOSH devrait être utilisée pour établir cette liste (à noter que la liste 2020 n'a pas encore été officiellement publiée par le NIOSH) : <https://www.cdc.gov/niosh/docket/review/docket233c/pdfs/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf>

Certains médicaments sont absents des listes du NIOSH, soit ils ne font pas partie des cibles du NIOSH, soit ils ne sont pas commercialisés aux États-Unis ou encore, soit ils n'ont pas encore été évalués, par exemple. Notamment, la liste 2020 du NIOSH tient compte des médicaments commercialisés jusqu'en décembre 2015. Le NIOSH ne précise pas si les médicaments absents de leur liste ont été évalués. Les critères utilisés pour les évaluations du NIOSH sont disponibles sur leur site : <https://www.cdc.gov/niosh/docs/2023-129/2023-129.pdf?id=10.26616/NIOSH PUB2023129>

Un sous-comité de la Communauté de pratique pour la manipulation sécuritaire des médicaments dangereux a été créé pour répondre au besoin exprimé par les établissements de santé du Québec d'avoir une liste harmonisée de médicaments dangereux.

Portée des travaux du sous-comité

Le sous-comité vise à évaluer les médicaments qui sont **absents** des listes NIOSH. Les médicaments pour lesquels une évaluation a déjà été réalisée par le NIOSH ne sont pas reconsidérés par le sous-comité.

L'évaluation est réalisée sur la base du danger potentiel de la molécule, le sous-comité ne tient pas compte de la formulation ni de la fréquence d'utilisation. Les évaluations du sous-comité sont réalisées conformément à la démarche du NIOSH :

<https://www.cdc.gov/niosh/docs/2023-129/2023-129.pdf?id=10.26616/NIOSH PUB2023129>

Le sous-comité liste de médicaments dangereux Québec

Annick Dufour, pharmacienne, CISSS Montérégie-Centre

Annie Langlais, pharmacienne, CHU de Québec – Université Laval

Audrey Chouinard, infirmière, Centre hospitalier de l'Université de Montréal et Université de Montréal

Cynthia Tanguay, spécialiste en activités cliniques, CHU Sainte-Justine

Jean-François Bussièrès, pharmacien, CHU Sainte-Justine

Jean-François Delisle, pharmacien, CHU Sainte-Justine

Lisa Labrecque, conseillère, ASSTSAS

Lysanne Besse, pharmacienne, Centre hospitalier de l'Université de Montréal

Marie-Noëlle Dupuis, pharmacienne, CISSS de la Gaspésie

Mélanie Drouin, pharmacienne, CISSS de Chaudière-Appalaches

Priti Wahi, pharmacienne, CIUSSS-de-l'Ouest-de-l'Île-de-Montréal

Sylvie Bédard, conseillère, ASSTSAS

Véronique Savard, infirmière, CHU de Québec – Université Laval

Contact : cynthia.tanguay.hsj@ssss.gouv.qc.ca

Avis important

Les membres du sous-comité qui ont préparé et discuté de ces évaluations ont révisé la documentation disponible au moment de l'évaluation avec soin, mais aucune garantie n'est fournie sur l'exactitude ou l'absence d'omission et elle ne peut pas couvrir toutes les utilisations et scénarios possibles. Le sous-comité n'est pas responsable de l'utilisation découlant de l'information utilisée dans cette liste. Il s'agit d'un outil de référence qui ne remplace pas le jugement d'un professionnel et il est important d'être familier avec le contexte d'utilisation.

Une analyse de risque locale doit être réalisée pour déterminer les mesures de précaution appropriées à l'utilisation locale selon la formulation utilisée.

IL EST INTERDIT D'UTILISER CETTE LISTE SANS ACCEPTER LES TERMES ET CONDITIONS CI-DESSOUS

Cette liste de médicaments dangereux, qui a initialement été préparée par de nombreux intervenants du réseau de la santé et des services sociaux (ci-après « RSSS ») et de l'ASSTSAS, a été créée dans le but qu'elle soit partagée avec l'ensemble des établissements du RSSS qui sont des établissements publics au sens de la *Loi sur les services de santé et les services sociaux*, RLRQ c. S-4.2 (ci-après « Établissement(s) »), et ce, dans une perspective de collaboration efficace entre les acteurs du RSSS.

En utilisant cette liste, vous vous engagez par contrat envers le sous-comité à respecter l'ensemble des conditions et modalités de la licence ci-dessous.

1 - Personnel et médecins d'Établissements seulement

Le sous-comité partage sa liste avec le personnel des Établissements, ainsi qu'avec les médecins qui y ont des privilèges de pratique, dans le cadre de leur pratique à l'intérieur des Établissements seulement (« Vous »).

Cette liste est partagée afin de guider les Établissements du RSSS dans la création de leur liste locale.

Toute autre personne, morale ou physique, qui accède à la présente liste afin de la consulter, l'utiliser, la reproduire, et/ou la partager d'une quelconque façon s'engage à accepter les termes et conditions de cet avis.

2 - Licence

Le sous-comité vous accorde une licence gratuite, limitée, non-commerciale, non exclusive, non cessible et non susceptible de sous-licence, Vous permettant de :

- Consulter la liste à la seule et unique fin de créer votre liste locale adaptée aux besoins de votre Établissement (« votre liste locale »);

- Reproduire, modifier, diffuser votre liste locale et en faire une utilisation professionnelle et non commerciale au sein de votre Établissement.

La présente licence ne vous accorde pas le droit d'autrement publier, distribuer, vendre ou faire toute autre utilisation commerciale ou non-commerciale de votre liste locale ou de celle du sous-comité.

3 – Non approbation

Rien dans la présente licence ne peut être interprété comme laissant supposer que vous ou que l'utilisation que vous faites de votre liste locale est liée à, parrainée, approuvée ou dotée d'un statut officiel par le sous-comité.

4 - Avertissements, limitations de garantie et de responsabilité

Le sous-comité met à disposition la liste telle quelle, et ne fait aucune représentation et ne fournit aucune garantie de quelque sorte que ce soit, notamment expresse, implicite, statutaire ou autre, en lien avec la suffisance, l'exactitude, l'exhaustivité, l'absence d'erreurs (connues ou susceptibles d'être découvertes) et la conformité de la liste, et ce, notamment eu égard à toute norme, obligation ou règle de conduite applicable, de quelque nature que ce soit, incluant notamment de nature scientifique, médicale, pharmaceutique, légale, législative, réglementaire, contractuelle, organisationnelle et/ou éthique.

Toute utilisation de votre liste locale en contexte clinique par tout professionnel, médecin ou autre, doit être faite de manière conforme à l'ensemble des obligations ou règles de conduite qui incombent à un tel professionnel, de quelle que nature que ce soit, incluant celles de nature civile, contractuelle et déontologique. Le contenu de la liste ne peut en aucun temps remplacer ou se substituer au jugement clinique du professionnel qui l'utilise.

Le sous-comité n'engage pas non plus sa responsabilité, quel qu'en soit le fondement juridique (y compris, notamment, la négligence), pour tout préjudice direct, spécial, indirect, incident, consécutif, punitif, exemplaire, ou pour toutes pertes, coûts, dépenses ou tout dommage découlant de l'utilisation de la présente licence ou de l'utilisation de la liste ou de votre liste locale, même si le sous-comité avait connaissance de l'éventualité de telles pertes, coûts, dépenses ou dommages.

Les avertissements, limitations de garantie et exclusions de responsabilité ci-dessus doivent être interprétés comme étant des limitations et renoncements totaux de toute responsabilité.

5 - Durée et fin

La présente licence s'applique pendant toute la durée de validité des droits accordés par la licence. Cependant, si Vous manquez aux obligations prévues par la présente licence, les droits qui Vous sont accordés par la présente licence seront automatiquement révoqués.

6 – Modifications à la licence

Aucune modification, amendement, changement ou ajout ultérieur à la présente licence par Vous ne liera le sous-comité aux présentes à moins que le sous-comité n'ait donné son accord écrit préalable.

7 - Utilisation du nom

Aucune utilisation du nom du sous-comité ou d'une variante de son nom ne peut être faite, pour des raisons publicitaires ou autres, sans l'accord écrit préalable du sous-comité.

8 - Cession et sous-licence

Cette licence lie Vos ayants droit et représentants légaux et Vous. La présente licence ne pourra être cédée ni sous-licenciée sans le consentement préalable écrit du sous-comité.

9 - Interprétation

Dans la mesure du possible, si une clause de la présente licence est déclarée inapplicable, elle sera automatiquement modifiée afin de la rendre applicable. Dans le cas où la clause ne pourrait être modifiée, elle sera écartée de la présente licence sans préjudice de l'applicabilité des termes et conditions restants.




10 - Contractants indépendants

Le sous-comité et Vous êtes des contractants indépendants pour les fins d'utilisation de la licence. La présente licence ne crée aucune relation d'emploi, de société ou de commettant-préposé.

Utilisation de la liste

La liste constitue un outil de référence pour que les établissements du RSSS créent leur liste locale de médicaments dangereux, et établissent leurs mesures de manipulations sécuritaires en vigueur.

Le document contient cinq tableaux :

- Médicaments « G1 »  et identifié par le code couleur « G1 »
- Médicaments « G2 »  et identifié par le code couleur « G2 »
- Médicaments « G3 »  et identifié par le code couleur « G3 »
- Médicaments qui n'ont pas été ajoutés à la liste (car ils ne rencontraient pas les critères d'un médicament dangereux)
- Médicaments qui n'ont pas été évalués (soit car ils seront évalués prochainement par le sous-comité, soit car ils ont été exclus de la portée des travaux du sous-comité)

Une définition sommaire est fournie au début de chaque tableau. Veuillez consulter la démarche publiée par le NIOSH pour comprendre les critères :

<https://www.cdc.gov/niosh/docs/2023-129/2023-129.pdf?id=10.26616/NIOSH PUB2023129>

Si applicable, les quatre premières colonnes présentent les classifications du NIOSH pour ce médicament en 2016 et en 2020, ainsi que toute précision qui accompagnait ce statut.

Si applicable, la colonne « Notice NIOSH » précise si le médicament a été mentionné dans une des « notices » du NIOSH. Les notices sont des documents explicatifs qui justifient certaines décisions du NIOSH.

La colonne « Sous-comité / groupe » indique le résultat de l'évaluation du sous-comité, incluant une précision à savoir si la décision découle d'une liste NIOSH ou de l'évaluation du sous-comité, et de la date de cette évaluation.

Médicaments « G1 »

Ce tableau contient les médicaments « G1 » :

- Soit ceux qui sont listés dans le tableau 1 de la liste 2020 du NIOSH.
- Soit ceux qui ont fait l'objet d'une notice publiée par le NIOSH faisant état que ce médicament était considéré comme inclus dans le tableau 1.
- Soit ceux qui ont été évalués comme « G1 » par le sous-comité, conformément aux critères de la démarche du NIOSH, soit :
 - contiennent des avis de précautions émis par les manufacturiers (MSHI)
 - présentent un risque cancérigène selon l'IARC (Groupe 1 « cancérigène pour l'Homme » ou groupe 2A « probablement cancérigène pour l'Homme »)
 - présentent un risque cancérigène selon le NTP (« Known to be Human Carcinogens »)



Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
altretamine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
amsacrine	Group 1-antineoplastic	MSHG; IARC Group 2B	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
arsenic trioxide	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen	Aucun	G1 (NIOSH)	
azacitidine	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Fitting criteria 2006 (cancer, pregnancy category D, repro tox, geno tox)	G1 (NIOSH)	
azathioprine	Group 2-non antineoplastic	MSHG; IARC Group 1 carcinogen†; NTP**; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
Bacillus Calmette Guerin (BCG)	Group 1-antineoplastic	MSHG; See special handling requirements‡; FDA Pregnancy Category C	Retiré	Retiré	Removed in 2020 draft list because "it is an infectious agent and not classified as a drug by FDA. For handling recommendations see drug package insert." + Notice 2020-09332 "only drugs approved by the CDER are included in the List"	G1-BCG	
belantamab mafodotin	Absent	Absent	Absent	Absent	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
belinostat	Group 1-antineoplastic	MSHG; May cause teratogenicity and/or embryo-fetal lethality because it is a genotoxic drug and targets actively dividing cells; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; May cause teratogenicity and/or embryo-fetal lethality because it is a genotoxic drug and targets actively dividing cells	Aucun	G1 (NIOSH)	
bendamustine hcl	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; Cytotoxic; Developmental toxicity	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
bleomycin	Group 1-antineoplastic	MSHG; IARC Group 2B; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
bortezomib	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox, organ tox, geno tox)	G1 (NIOSH)	
brentuximab vedotin	Group 1-antineoplastic	MSHG; Conjugated monoclonal antibody; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; Monoclonal antibody conjugated to vedotin	Aucun	G1 (NIOSH)	
busulfan	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen	Aucun	G1 (NIOSH)	
cabazitaxel	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
capecitabine	Group 1-antineoplastic	MSHG; Metabolized to 5-fluorouracil; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; Metabolized to 5-fluorouracil	Aucun	G1 (NIOSH)	
carboplatin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
carmustine	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
chlorambucil	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
chloramphenicol	Group 2-non antineoplastic	IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category C	Table 1-carcinogen	IARC Group 2A carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
cidofovir	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category C	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
cisplatin	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
cladribine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, organ tox, geno tox)	G1 (NIOSH)	
clofarabine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, geno tox)	G1 (NIOSH)	
cyclophosphamide	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
cyclosporine	Group 2-non antineoplastic	IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category C	Table 1-carcinogen	IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
cytarabine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
dacarbazine	Group 1-antineoplastic	MSHG; NTP***; FDA Pregnancy Category C	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
dactinomycin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
dasatinib	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox)	G1 (NIOSH)	
daunorubicin hcl	Group 1-antineoplastic	MSHG; IARC Group 2B, AKA daunomycin; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2B; AKA daunomycin	Aucun	G1 (NIOSH)	
decitabine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, organ tox, geno tox)	G1 (NIOSH)	
decitabine-cedazuridine (*)	Absent	Absent	Absent	Absent	Aucun	G1 (sous-comité)	2024-01-09
dexrazoxane	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category C; secondary malignancies observed in patients treated long term with Razoxane (a racemic mixture containing dexrazoxane); genotoxic in vitro and in vivo; in laboratory studies, testicular atrophy observed at or below the human dose	Table 1-carcinogen	MSHI; Secondary malignancies observed in patients treated long term with Razoxane (a racemic mixture containing dexrazoxane); Genotoxic in vitro and in vivo; in laboratory studies, Testicular atrophy observed at or below the human dose	Not fitting criteria 2006	G1 (NIOSH)	
diethylstilbestrol	Group 2-non antineoplastic	IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category X	Table 1-carcinogen	IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
docetaxel	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
doxorubicin	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
enfortumab vedotin	Absent	Absent	Table 1-carcinogen	MSHI; Monoclonal antibody conjugated to vedotin; Cytotoxic; Developmental toxicity	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
epirubicin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
estramustine phosphate (estramustine phosphate sodium) (estramustine)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category X	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
estrogen/ progestin combinations (estrogen/progesterone combinations)	Group 2-non antineoplastic	IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category X	Table 1- carcinogen	IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
estrogens, conjugated	Group 2-non antineoplastic	Black Box warning for endometrial cancer and cardiovascular risks; long-term use in women and laboratory studies increases frequency of several cancers; NTP**; FDA Pregnancy Category X	Table 1- carcinogen	NTP "known to be human carcinogen"; Black Box warning for endometrial cancer and cardiovascular risks; Long-term use in women and laboratory studies increases frequency of several cancers	Aucun	G1 (NIOSH)	
estrogens, esterified	Group 2-non antineoplastic	Black Box warning for endometrial cancer and cardiovascular risks; NTP**; FDA Pregnancy Category X	Table 1- carcinogen	NTP "known to be human carcinogen"; Black Box warning for endometrial cancer and cardiovascular risks	Aucun	G1 (NIOSH)	
etoposide	Group 1- antineoplastic	MSHG; IARC Group 1 carcinogen; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; IARC Group 1 carcinogen	Aucun	G1 (NIOSH)	
everolimus	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
floxuridine	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
fludarabine	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
fluorouracil	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
ganciclovir	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category C	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
gemcitabine	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Notice 2020-09332 "no proposing to place it on the list but this drug is scheduled to be reviewed for the update after the 2020 List update"	G1 (NIOSH)	
gemtuzumab ozogamicin	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; Monoclonal antibody conjugated to ozogamicin; Cytotoxic; Developmental toxicity	Aucun	G1 (NIOSH)	
hydrate de chloral 🇵🇸	Absent	Absent	Absent	Absent	Aucun	G1 (sous-comité)	2024-01-09
hydroxyurea	Group 1- antineoplastic	MSHG; Special warning on handling bottles and capsules; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; Special warning on handling bottles and capsules	Aucun	G1 (NIOSH)	
idarubicin	Group 1- antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
ifosfamide	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
imatinib mesylate (imatinib)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer, pregnancy category D, repro tox, organ tox, geno tox)	G1 (NIOSH)	
inotuzumab ozogamicin	Absent	Absent	Table 1-carcinogen	MSHI; Monoclonal antibody conjugated to ozogamicin; Cytotoxic; Developmental toxicity	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs" + Notice 2020-09332 "MSHI and automatically added to the 2016 List"	G1 (NIOSH)	
irinotecan hcl	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
ixabepilone	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
ixazomib	Group 1-antineoplastic	MSHG; Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment	Table 1-carcinogen	MSHI; Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment	Aucun	G1 (NIOSH)	
lenalidomide	Group 2-non antineoplastic	MSHG; Analog of thalidomide; FDA Black Box warnings for limb abnormalities; Pregnancy Category X; in laboratory studies, caused thalidomide-type limb defects in monkey offspring	Table 1-carcinogen	MSHI; Analog of thalidomide; FDA Black box warnings for limb abnormalities; in laboratory studies, caused thalidomide-type limb defects in monkey offspring	Fitting criteria 2006 (cancer not tested, pregnancy category X, organ tox)	G1 (NIOSH)	
lomustine	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
loncastuximab tesirine	Absent	Absent	Absent	Absent	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
lurbinectedine	Absent	Absent	Absent	Absent	Notice 9MAY2023. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	2022-11-08
mechlorethamine (chlorméthine)	Group 1-antineoplastic	MSHG; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
melfalan	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
mercaptopurine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
methotrexate	Group 1-antineoplastic	MSHG; FDA Pregnancy Category X	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
mirvetuximab soravtansine	Absent	Absent	Absent	Absent	Notice 9MAY2023. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
mitomycin	Group 1-antineoplastic	MSHG; IARC Group 2B; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
mitotane	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
mitoxantrone hcl	Group 1-antineoplastic	MSHG; IARC Group 2B; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
nelarabine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox not tested, organ tox, geno tox)	G1 (NIOSH)	
omacetaxin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
oxaliplatin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
paclitaxel	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
panobinostat	Group 1-antineoplastic	MSHG; Special warnings on contraception for females while taking and 1 month post-treatment;	Table 1-carcinogen	MSHI; Special warnings on contraception for females while taking and one month post-treatment	Aucun	G1 (NIOSH)	
pemetrexed	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox, organ tox, geno tox)	G1 (NIOSH)	
pentostatin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
polatuzumab vedotin	Absent	Absent	Table 1-carcinogen	MSHI; Monoclonal antibody conjugated to vedotin; Cytotoxic; Developmental toxicity	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs" + Notice 2020-09332 "MSHI and will appear in the 2020 List"	G1 (NIOSH)	
pomalidomide	Group 1-antineoplastic	MSHG; Females of reproductive potential must use two forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping treatment; FDA Pregnancy Category X	Table 1-carcinogen	MSHI; Analog of thalidomide; Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping treatment	Aucun	G1 (NIOSH)	
pralatrexate	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
procarbazine	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
raltitrexed	Absent	Absent	Absent	Absent	Removed in 2012 list because not available in the US	G1 (sous-comité)	2023-01-13
romidepsin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
sacituzumab govitecan	Absent	Absent	Table 1-carcinogen	MSHI, Ajouté en 2021 selon notice en ligne	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
streptozocin	Group 1-antineoplastic	MSHG; IARC Group 2B; NTP***; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
tamoxifen	Group 1-antineoplastic	IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category D	Table 1-carcinogen	IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
temozolomide	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
temsirolimus	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
teniposide	Group 1-antineoplastic	MSHG; IARC Group 2A carcinogen; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 2A carcinogen	Aucun	G1 (NIOSH)	
thalidomide	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category X	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
thioguanine	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Aucun	G1 (NIOSH)	
thiotepa	Group 1-antineoplastic	MSHG; IARC Group 1 carcinogen; NTP**; FDA Pregnancy Category D	Table 1-carcinogen	MSHI; IARC Group 1 carcinogen; NTP "known to be human carcinogen"	Aucun	G1 (NIOSH)	
tisotumab vedotin-tftv	Absent	Absent	Absent	Absent	Notice 23MAR2022. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
topotecan	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1-carcinogen	MSHI	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, organ tox, genotox)	G1 (NIOSH)	
trabectedin	Absent	Absent	Table 1-carcinogen	MSHI; Cytotoxic; Genotoxic	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs" + Notice 2020-09332 "MSHI and automatically added to the 2016 List" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (manufacturer special handling information)	G1 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notices NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
trastuzumab deruxtecan	Absent	Absent	Table 1- carcinogen	MSHI; Monoclonal antibody conjugated to deruxtecan; Cytotoxic	Notice 28MAY2021. "Manufacturers recommend that they be handled as hazardous drugs. Therefore, NIOSH considers these drugs to be included in Table 1 of the NIOSH list of hazardous drugs"	G1 (NIOSH)	
trastuzumab emtansine (ou ado-trastuzumab emtansine)	Group 1-antineoplastic	MSHG; Conjugated monoclonal antibody; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; Monoclonal antibody conjugated to mertansine (emtansine)	Aucun	G1 (NIOSH)	
treosulfan	Absent	Absent	Absent	Absent	Aucun	G1 (sous-comité)	2022-12-13
trifluridine /tipiracil (en combinaison)	Group 1-antineoplastic	MSHG; Embryo-fetal lethality and embryo-fetal toxicity at doses lower than or similar to exposures at the recommended human dose	Table 1- carcinogen	MSHI; Embryo-fetal lethality and embryo-fetal toxicity at doses lower than or similar to exposures at the recommended human dose [note du sous-comité : ce médicament est indiqué comme trifluridine seul avec la classe AHFS 10:00 dans la liste 2020, ceci nous apparait une erreur]	Aucun	G1 (NIOSH)	2023-11-14
uracil mustard	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; IARC Group 2B	Aucun	G1 (NIOSH)	
valganciclovir	Group 2-non antineoplastic	MSHG; FDA Pregnancy Category C	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
valrubicin	Group 1-antineoplastic	MSHG; FDA Pregnancy Category C	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
vandetanib	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
vinblastine sulfate (vinblastine)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
vincristine sulfate (vincristine)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
vinorelbine tartrate (vinorelbine)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category D	Table 1- carcinogen	MSHI	Aucun	G1 (NIOSH)	
vorinostat	Group 1-antineoplastic	MSHG; Adverse embryo-fetal effects at less than the recommended human dose; FDA Pregnancy Category D	Table 1- carcinogen	MSHI; Adverse embryo-fetal effects at less than the recommended human dose	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, geno tox)	G1 (NIOSH)	

Légende : FDA : Food and Drug Administration, IARC : International Agency for Research on Cancer, MSHG : manufacturer safe handling guidelines, MSHI : manufacturer's safe handling instructions, NIOSH : National Institute for Occupational Safety and Health, NTP : National Toxicology Program

G1-BCG : selon les précautions du Guide de l'ASSTSAS (2021)

(*) : indique qu'il s'agit d'un ajout par rapport à la liste précédente. Code couleur : « G1 » et « G2 »

Médicaments « G2 »

Ce tableau contient les médicaments « G2 » :



- Soit ceux qui sont listés dans le tableau 2 de la liste 2020 du NIOSH (sans mention qu'ils présentent uniquement un risque développemental ou de la reproduction)
- Soit ceux qui ont été évalués comme « G2 » par le sous-comité, conformément aux critères de la démarche du NIOSH, soit :
 - comportent d'autres dangers selon la définition du NIOSH (génétoxicité, toxique pour un organe à faible dose)
 - présentent un risque cancérigène, mais ne rencontrent pas la définition d'un G1 (classé Groupe 2B « peut-être cancérigène pour l'Homme » ou Groupe 3 « inclassable quant à sa cancérigénicité pour l'Homme » par l'IARC, classé « Reasonably Anticipated To Be Human Carcinogen » par le NTP ou non classé par ces deux organismes, mais présentent des évidences de cancérigénicité dans d'autres sources comme dans la monographie).

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
abacavir	Group 2-non antineoplastic	FDA Pregnancy Category C; malignant tumors observed in male and female mice and rats; genotoxic in in vivo micronucleus test	Table 2-noMSHI-not carcinogen	Malignant tumors observed in male and female mice and rats; Genotoxic in vivo micronucleus test.	Aucun	G2 (NIOSH)	
abémaciclib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-02-07
acalabrutinib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-02-14
afatinib	Group 1-antineoplastic	Special warnings on contraception for females while taking and 2 weeks post-treatment; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Special warnings on contraception for females while taking and two weeks post-treatment	Proposed addition 2016 "Pregnancy category category D, table 1"	G2 (NIOSH)	
alefacept	Group 2-non antineoplastic	Increased frequency of malignancies observed in treated patients; FDA Pregnancy Category B	Table 2-noMSHI-not carcinogen	Increased frequency of malignancies observed in treated patients	Aucun	G2 (NIOSH)	
apomorphine	Group 2-non antineoplastic	FDA Pregnancy Category C; genotoxic in several in vitro assays	Table 2-noMSHI-not carcinogen	Genotoxic in several in vitro assays	Fitting criteria 2006 (cancer not tested, pregnancy category C)	G2 (NIOSH)	
axitinib	Group 1-antineoplastic	Teratogenic, embryotoxic and fetotoxic in mice at exposures lower than human exposures; FDA Pregnancy category D	Table 2-noMSHI-not carcinogen	Teratogenic, embryotoxic and fetotoxic in mice at exposures lower than human exposures	Aucun	G2 (NIOSH)	
baricitinib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2022-10-11

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
bicalutamide	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	
blinatumomab	Absent	Absent	Table 2-noMSHI-not carcinogen	Organ Toxicity at Low Dose - Neurotoxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (organ toxicity at low doses) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (organ toxicity at low doses)	G2 (NIOSH)	
carbamazepine	Group 2-non antineoplastic	Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Category D*	Table 2-noMSHI-not carcinogen	Black Box warning for aplastic anemia; Congenital malformations in offspring of mothers who took drug; Rapid transplacental passage	Aucun	G2 (NIOSH)	
crizotinib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	
cyproterone	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2022-11-08
dabrafenib	Group 1-antineoplastic	Special warnings on contraception for females while taking and 2 weeks post-treatment; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Special warnings on contraception for females while taking and two weeks post-treatment	Aucun	G2 (NIOSH)	
deferiprone	Group 2-non antineoplastic	Genotoxic in vitro and in vivo; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Genotoxic in vitro and in vivo	Aucun	G2 (NIOSH)	
dienogest (estradiol valerate)	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2022-11-22
encorafénib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-04-11
entecavir	Group 2-non antineoplastic	FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	Aucun	Fitting criteria 2006 (cancer, pregnancy category C, geno tox)	G2 (NIOSH)	
eribulin	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
estradiol	Group 2-non antineoplastic	Black Box warning for malignant neoplasms; increased risk of endometrial cancer, breast cancer, and ovarian cancer; in laboratory studies, increased frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver; present in breast milk; FDA Pregnancy Category X	Table 2- noMSHI-not carcinogen	Black Box warning for malignant neoplasms; Increased risk of endometrial cancer, breast cancer, and ovarian cancer; in laboratory studies, increased frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver; Present in breast milk	Aucun	G2 (NIOSH)	
estropipate	Group 2-non antineoplastic	Black Box warning for endometrial carcinoma in postmenopausal women and use during pregnancy; FDA Pregnancy Category X	Table 2- noMSHI-not carcinogen	Black Box warning for endometrial carcinoma in postmenopausal women and use during pregnancy	Aucun	G2 (NIOSH)	
exenatide	Absent	Absent	Table 2- noMSHI-not carcinogen	Carcinogenicity; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (carcinogenicity and teratogenicity or other developmental toxicity)+ Not fitting criteria 2006 + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (carcinogenicity and teratogenicity or other developmental toxicity)	G2 (NIOSH)	
fingolimod	Group 2-non antineoplastic	FDA Pregnancy Category C; in laboratory studies, increased malformations and embryo-fetal deaths at less than the recommended human dose; malignant lymphomas observed in male and female mice	Table 2- noMSHI-not carcinogen	In laboratory studies, increased malformations and embryo-fetal deaths at less than the RHD; Malignant lymphomas observed in male and female mice	Aucun	G2 (NIOSH)	
fluoxymesterone	Group 2-non antineoplastic	Tumors in mice and rats and possibly humans; FDA Pregnancy Category X	Table 2- noMSHI-not carcinogen	Tumors in mice and rats and possibly humans	Aucun	G2 (NIOSH)	
flutamide	Group 1- antineoplastic	Indicated only for men; FDA Pregnancy Category D	Table 2- noMSHI-not carcinogen	Indicated only for men	Aucun	G2 (NIOSH)	
fosphenytoin	Group 2-non antineoplastic	Metabolized to phenytoin; FDA Pregnancy Category D	Table 2- noMSHI-not carcinogen	Metabolized to phenytoin	Aucun	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
ibrutinib	Absent	Absent	Absent	Absent	Notice 2020-09332 "no proposing to place it on the list" (ibrutinib had developmental effects in animals but only at doses twice the maximum recommended human dose of 560 mg/day,) + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	G2 (sous-comité)	2023-02-15
leflunomide	Group 2-non antineoplastic	Teratogenic in laboratory studies at 1/10 human dose (HD); marked postnatal survival at 1/100 HD; FDA Pregnancy Category X; severe liver injury reported in patients; carcinogenicity observed at doses below HD	Table 2-noMSHI-not carcinogen	Teratogenic in laboratory studies at 1/10 HD; Marked postnatal survival at 1/100 HD; Severe liver injury reported in patients; Carcinogenicity observed at doses below HD	Aucun	G2 (NIOSH)	
liraglutide recombinant	Group 2-non antineoplastic	FDA Pregnancy Category C; Black Box warning for thyroid C-cell tumors, with supporting evidence in laboratory studies; also in laboratory studies, teratogenic at or below the MRHD	Table 2-noMSHI-not carcinogen	Black Box warning for thyroid C-cell tumors, with supporting evidence in laboratory studies; In laboratory studies, teratogenic at or below the MRHD	Aucun	G2 (NIOSH)	
megestrol	Group 1-antineoplastic	MSHG; Nursing should be discontinued if megestrol is required; women at risk of pregnancy should avoid exposure; FDA Pregnancy Category X	Table 2-noMSHI-not carcinogen	Nursing should be discontinued if megestrol is required; Women at risk of pregnancy should avoid exposure	Aucun	G2 (NIOSH)	
methimazole	Group 2-non antineoplastic	Appears in human breast milk; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Appears in human breast milk	Aucun	G2 (NIOSH)	
mipomersen	Group 2-non antineoplastic	Black Box warning on hepatotoxicity; FDA Pregnancy Category B	Table 2-noMSHI-not carcinogen	Black box warning of hepatotoxicity	Aucun	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
mycophenolate mofetil	Group 2-non antineoplastic	Black Box warning for embryo fetal toxicity, malignancies, and serious infections; increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; FDA Pregnancy Category D; Special warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in capsules and oral suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.	Table 2-noMSHI-not carcinogen	Black Box warning for embryo fetal toxicity, malignancies and serious infections; Increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special warning: tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in capsules and oral suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.	Aucun	G2 (NIOSH)	
mycophenolic acid	Group 2-non antineoplastic	Black Box warning for first trimester pregnancy loss and an increased risk of congenital malformations; FDA Pregnancy Category D; Black Box warning for lymphomas and other malignancies; genotoxic in vitro and in vivo	Table 2-noMSHI-not carcinogen	Black Box warning for embryo fetal toxicity, malignancies and serious infections; Increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Black Box warning for lymphomas and other malignancies; genotoxic in vitro and in vivo	Aucun	G2 (NIOSH)	
nevirapine	Group 2-non antineoplastic	FDA Pregnancy Category B; in laboratory studies, hepatocellular adenomas and carcinomas at doses lower than human dose	Table 2-noMSHI-not carcinogen	In laboratory studies, hepatocellular adenomas and carcinomas at doses lower than human dose	Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
niraparib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-11-14
olaparib	Absent	Absent	Table 2-noMSHI-not carcinogen	Genotoxicity; Developmental toxicity	Notice 2020-09332 "proposes to place it on the list" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (carcinogenicity and teratogenicity or other developmental toxicity) + Commentaires 2018 (carcinogenicity and teratogenicity or other developmental toxicity)	G2 (NIOSH)	
ospemifene	Group 2-non antineoplastic	Black Box warning on increased risk of endometrial cancer in certain populations; risk of adverse outcomes during pregnancy and labor; FDA Pregnancy Category X	Table 2-noMSHI-not carcinogen	Black box warning on increased risk of endometrial cancer in certain populations; Risk of adverse outcomes during pregnancy and labor	Aucun	G2 (NIOSH)	
oxcarbazepine	Group 2-non antineoplastic	Tumors observed in laboratory studies at 1/10 MRHD; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	Tumors observed in laboratory studies at 1/10 MRHD	Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)	G2 (NIOSH)	
palifermin	Group 2-non antineoplastic	FDA Pregnancy Category C; potential for stimulation of tumor growth	Table 2-noMSHI-not carcinogen	Potential for stimulation of tumor growth	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox)	G2 (NIOSH)	
phenoxybenzamine hcl	Group 2-non antineoplastic	IARC Group 2B; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	IARC Group 2B	Aucun	G2 (NIOSH)	
phenytoin	Group 2-non antineoplastic	IARC Group 2B; NTP***; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	IARC Group 2B	Aucun	G2 (NIOSH)	
pipobroman	Group 2-non antineoplastic	FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	
ponatinib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	
progesterone	Group 2-non antineoplastic	IARC Group 2B; NTP***	Table 2-noMSHI-not carcinogen	IARC Group 2B	Aucun	G2 (NIOSH)	
progestins	Group 2-non antineoplastic	FDA Pregnancy Category X	Table 2-noMSHI-not carcinogen	Aucun	Aucun	G2 (NIOSH)	
propylthiouracil	Group 2-non antineoplastic	IARC Group 2B; NTP***; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	IARC Group 2B	Aucun	G2 (NIOSH)	
raloxifene	Group 2-non antineoplastic	Abortion and developmental abnormalities seen at low doses in laboratory	Table 2-noMSHI-not carcinogen	Abortion and developmental abnormalities seen at low doses in laboratory	Aucun	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
		studies; evidence of tumors at low doses in laboratory studies; FDA Pregnancy Category X		studies; Evidence of tumors at low doses in laboratory studies			
rasagiline mesylate (rasagiline)	Group 2-non antineoplastic	FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	Aucun	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (cancer, pregnancy category C, geno tox)	G2 (NIOSH)	
ribociclib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2022-12-13
semaglutide	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-04-11
sirolimus	Group 2-non antineoplastic	AKA rapamycin; increased risk of lymphomas and other malignancies; embryotoxic and fetotoxic at 0.2 human dose; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	AKA rapamycin; Increased risk of lymphomas and other malignancies; Embryotoxic and fetotoxic at 0.2 HD	Fitting criteria 2006 (cancer, pregnancy category C, repro tox)	G2 (NIOSH)	
spironolactone	Group 2-non antineoplastic	FDA Pregnancy Category C; Black Box warning for tumorigenicity in laboratory studies	Table 2-noMSHI-not carcinogen	Black box warning for tumorigenicity in laboratory studies	Aucun	G2 (NIOSH)	
sunitinib malate (sunitinib)	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Aucun	Fitting criteria 2006 (cancer not tested, pregnancy category D, repro tox, organ tox, geno tox not tested)	G2 (NIOSH)	
tacrolimus	Group 2-non antineoplastic	Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	Increased risk of lymphomas and other malignancies; Reproductive effects seen in laboratory studies below the MRHD; Excreted in breast milk	Aucun	G2 (NIOSH)	
talazoparib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-11-14
teriflunomide	Group 2-non antineoplastic	Black Box warning on severe hepatotoxicity and teratogenicity, including major birth defects; FDA Pregnancy Category X	Table 2-noMSHI-not carcinogen	Black box warning on severe hepatotoxicity and teratogenicity including major birth defects	Aucun	G2 (NIOSH)	
tofacitinib	Group 2-non antineoplastic	Black Box warning for lymphoma and other malignancies; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	Black box warning for lymphoma and other malignancies	Aucun	G2 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
trametinib	Group 1-antineoplastic	Embryotoxic and abortifacient at doses less than recommended human dose; FDA Pregnancy Category D	Table 2-noMSHI-not carcinogen	Embryotoxic and abortifacient at doses less than recommended human dose	Aucun	G2 (NIOSH)	
upadacitinib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-03-14
venetoclax	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-06-13
zanubrutinib	Absent	Absent	Absent	Absent	Aucun	G2 (sous-comité)	2023-02-14
zidovudine	Group 2-non antineoplastic	IARC Group 2B; FDA Pregnancy Category C	Table 2-noMSHI-not carcinogen	IARC Group 2B	Aucun	G2 (NIOSH)	

Légende : FDA : Food and Drug Administration, IARC : International Agency for Research on Cancer, MSHG : manufacturer safe handling guidelines, MSHI : manufacturer's safe handling instructions, NIOSH : National Institute for Occupational Safety and Health, NTP : National Toxicology Program

Code couleur : « G1 » et « G2 »

Médicaments « G3 »

Ce tableau contient les médicaments « G3 » :

- Soit ceux qui sont listés dans le tableau 2 de la liste 2020 du NIOSH (avec mention qu'ils présentent uniquement un risque développemental ou de la reproduction).
- Soit ceux qui ont été évalués comme « G3 » par le sous-comité, conformément aux critères de la démarche du NIOSH, soit :
 - comportent uniquement un risque développemental ou pour la reproduction selon la définition du NIOSH.



Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
abiraterone	Group 1-antineoplastic	Women who are pregnant or may be pregnant should not handle without protection (e.g., gloves); FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Women who are pregnant or women who may be pregnant should not handle without protection (e.g., gloves)	Aucun	G3 (NIOSH)	
acitretin	Group 3-reproductive effects	Black Box warning on adverse reproductive effects; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
aflibercept	Group 1-antineoplastic	Embryotoxic and teratogenic in rabbits at exposure levels lower than human exposures at the recommended dose, with increased incidences of external, visceral, and skeletal fetal malformations; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Embryotoxic and teratogenic in rabbits at exposure levels lower than human exposures at the recommended dose, with increased incidences of external, visceral, and skeletal fetal malformations	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	G3 (NIOSH)	
alitreinoïd	Group 3-reproductive effects	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
alpelisib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-10-10

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
ambrisentan	Group 3-reproductive effects	Black Box warning on adverse reproductive effects; reduced sperm counts in patients; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
amifampridine (et phosphate d'amifampridine)	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-10-10
anastrozole	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
apalutamide	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-10-04
asciminib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-11-22
avapritinib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-04-11
bexarotene	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
bosentan	Group 3-reproductive effects	Black Box warning on adverse reproductive effects; Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer, pregnancy category X, repro tox, organ tox)	G3 (NIOSH)	
bosutinib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
brigatinib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-06-13
busereline	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-10-11
cabergoline	Group 3-reproductive effects	Inhibition of conception and embryo fetal effects at doses below recommended human dose; FDA Pregnancy Category B	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
cabozantinib	Group 1-antineoplastic	Embryolethal in rats at exposures below the recommended human dose; FDA Pregnancy category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Embryo lethal in rats at exposures below the recommended human dose	Aucun	G3 (NIOSH)	
capmatinib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-02-07
carfilzomib	Group 1-antineoplastic	Special warnings on contraception while taking and 2 weeks post-treatment; FDA Pregnancy category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Special warnings on contraception while taking and two weeks posttreatment	Aucun	G3 (NIOSH)	
ceritinib	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (teratogenicity or other developmental toxicity) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
cetorelix acetate (cetorelix)	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
choriogonadotropin alfa (choriogonadotropin)	Group 3-reproductive effects	FDA Pregnancy Category X; may cause fetal harm when administered to a pregnant woman	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Aucun	G3 (NIOSH)	
clobazam	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity; Reproductive toxicity-male; Reproductive toxicityfemale	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (reproductive toxicity and teratogenicity or other developmental toxicity) +Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity and teratogenicity or other developmental toxicity)	G3 (NIOSH)	
clomiphene	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
clonazepam	Group 3-reproductive effects	Increased risk of congenital abnormalities when taken in first trimester; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
cobimetinib	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity; Reproductive toxicity-male; Reproductive toxicity-female	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (reproductive toxicity and teratogenicity or other developmental toxicity) +Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity and teratogenicity or other developmental toxicity)	G3 (NIOSH)	
colchicine	Group 3-reproductive effects	FDA Pregnancy Category C; published animal reproduction and development studies indicate it causes embryofetal toxicity, teratogenicity, and altered postnatal development at exposures within or above the clinical therapeutic range	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
danazol 🇵🇸	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2024-03-12
darolutamide	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-10-10
degarelix	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
dihydroergotamine	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (reproductive toxicity) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity)	G3 (NIOSH)	
dinoprostone	Group 3-reproductive effects	Hazardous only for women in late pregnancy; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
divalproex	Group 2-non antineoplastic	Black Box warning for teratogenicity; FDA Pregnancy Category D; tumors seen in laboratory studies at doses below MRHD	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Black box warning on embryo-fetal death or severe birth defects; Recommend effective contraception for females during therapy and for seven months after treatment; Present in semen; No sperm donation during and three months post-treatment	Fitting criteria 2006 (cancer, pregnancy category D, organ tox)	G3 (NIOSH)	
dronedarone hcl	Group 3-reproductive effects	Teratogenic in laboratory studies at ½ MRHD; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
dutasteride	Group 3-reproductive effects	Women warned not to handle; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
enzalutamide	Group 1-antineoplastic	Embryo-fetal toxicity in mice at exposures that were lower than in patients receiving the recommended dose; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Embryo-fetal toxicity in mice at exposures that were lower than in patients receiving the recommended dose	Aucun	G3 (NIOSH)	
ergonovine/methylergo novine	Group 3-reproductive effects	Use is contraindicated during pregnancy because of its uterotonic effects; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity – third trimester	Aucun	G3 (NIOSH)	
erlotinib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer not tested, pregnancy category D)	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
eslicarbazepine	Group 3-reproductive effects	Fetal malformations, fetal growth retardation, embryoletality, and reduced body weights observed in animal studies; excreted in human breast milk; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
exemestane	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
fedratinib (*)	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2023-12-12
finasteride	Group 3-reproductive effects	Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant, due to potential risk to a male fetus; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
fluconazole	Group 3-reproductive effects	FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400–800 mg/ day) during most or all of the first trimester, similar to those seen in animal studies	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Notice 2020-09332 "meets the NIOSH criteria for hazardous drugs"	G3 (NIOSH)	
fulvestrant	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
ganirelix acetate (ganirelix)	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
gonadotropin, chorionic	Group 3-reproductive effects	Defects of forelimbs and central nervous system and alterations in sex ratio have been reported in laboratory studies; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
goserelin	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
histrelin	Group 1-antineoplastic	Can cause fetal harm when administered to a pregnant patient, with the possibility of spontaneous abortion; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Can cause fetal harm when administered to a pregnant patient with the possibility of spontaneous abortion	Aucun	G3 (NIOSH)	
icatibant	Group 3-reproductive effects	FDA Pregnancy Category C; in laboratory studies, premature birth and abortion rates increased at a dose that was less than 1/40th the MRHD, and delayed parturition and fetal death occurred at 0.5 and 2-fold, respectively, the MRHD	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
isotretinoïne	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (teratogenicity or other developmental toxicity)+ Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
ivabradine	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
larotrectinib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-12-13
lenvatinib	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity) + Commentaires 2018 (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
letrozole	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
leuprolide acetate (leuprolide)	Group 1-antineoplastic	MSHG; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
lomitapide	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
lorlatinib (L)	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2024-02-13
lutropine alfa	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-10-11
macitentan	Group 3-reproductive effects	Black Box warning for embryo-fetal toxicity; special warnings on contraception for females while taking and 1 month post-treatment; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
medroxyprogesterone acetate	Group 2-non antineoplastic	MSHG; IARC Group 2B; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; IARC Group 2B	Fitting criteria 2006 (pregnancy category X, repro tox)	G3 (NIOSH)	
menotropins	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
methyltestosterone	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
midostaurine	Absent	Absent	Absent	Absent	Notice 2020-09332 "This drug is scheduled to be reviewed for the next List update"	G3 (sous-comité)	2023-02-07
mifepristone	Group 3-reproductive effects	When given to pregnant women, results in termination of pregnancy; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux


Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
miltefosine	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity; Reproductive toxicity – male; Reproductive toxicity –female	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (teratogenicity or other developmental toxicity) +Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
misoprostol	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
nafarelin	Group 3-reproductive effects	Note: Given only as nasal spray; no potential for occupational exposure; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
neratinib (*)	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2024-01-09
nilotinib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
oxytocin	Group 3-reproductive effects	Hazardous only for women in 3rd trimester; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity – third trimester	Aucun	G3 (NIOSH)	
pamidronate	Group 3-reproductive effects	Embryo-fetal toxicities at doses below the recommended human dose; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
paroxetine hcl (paroxetine)	Group 3-reproductive effects	Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in third trimester; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer , pregnancy category D, repro tox)	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
pasireotide	Group 3-reproductive effects	Increased implantation loss and decreased viable fetuses, corpora lutea, and implantation sites at doses less than the human recommended dose; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
pazopanib hcl	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
peginesatide	Group 3-reproductive effects	Adverse embryo-fetal effects, including reduced fetal weight, increased resorption, embryo-fetal lethality, and cleft palate, observed in doses below the recommended human dose; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
pemigatinib 	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2024-03-12
pentetate calcium trisodium	Group 3-reproductive effects	Severe teratogenic effects in laboratory studies in dogs; supplied in ampule, which can lead to occupational exposure; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox)	G3 (NIOSH)	
plerixafor	Group 3-reproductive effects	Teratogenic in laboratory studies; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
regorafenib	Group 1-antineoplastic	Black Box warning on severe and sometimes fatal hepatotoxicity; total loss of pregnancy at doses lower than recommended human dose; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Black box warning on severe and sometimes fatal hepatotoxicity; Total loss of pregnancy at doses lower than recommended human dose	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
ribavirin	Group 3-reproductive effects	Teratogenic and embryotoxic effects in several laboratory studies; contraindicated in women who are pregnant and in the male partners of women who are pregnant; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
riociguat	Group 3-reproductive effects	Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
sonidegib	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity; Reproductive toxicity – female	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (reproductive toxicity and teratogenicity or other developmental toxicity) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity and teratogenicity or other developmental toxicity)	G3 (NIOSH)	
sorafenib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer not tested, pregnancy category B, organ tox)	G3 (NIOSH)	
temazepam	Group 3-reproductive effects	Increased risk of congenital malformations associated with treatment during the first trimester of pregnancy; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
tepotinib	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2022-12-13
testosterone	Group 3-reproductive effects	Children should avoid contact with unwashed or unclothed application sites on skin; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
topiramate	Group 3-reproductive effects	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH					Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
toremifene citrate (toremifene)	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
tretinoin	Group 3-reproductive effects	Black Box warning for severe birth defects; Special FDA distribution system; FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
triptorelin	Group 1-antineoplastic	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
tucatinib (*)	Absent	Absent	Absent	Absent	Aucun	G3 (sous-comité)	2024-01-09
ulipristal	Group 3-reproductive effects	FDA Pregnancy Category X	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
urofollitropin	Absent	Absent	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Developmental toxicity	Notice 2020-09332 "proposed for 2020 List" + Commentaires 2018 (teratogenicity or other developmental toxicity) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity)	G3 (NIOSH)	
valproate/valproic acid (valproic acid/divalproex na)	Group 3-reproductive effects	Black Box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer, pregnancy category D, repro tox, organ tox)	G3 (NIOSH)	
vemurafenib	Group 1-antineoplastic	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
vigabatrin	Group 3-reproductive effects	Malformations seen in laboratory studies below the MRHD; FDA Pregnancy Category C	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	G3 (NIOSH)	

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020		Groupe	Date d'évaluation
vismodegib	Group 1-antineoplastic	Black Box warning on embryo-fetal death or severe birth defects; recommend effective contraception for females during therapy and for 7 months after treatment; present in semen; no sperm donation during and 3 months post-treatment; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard; Black box warning on embryo-fetal death or severe birth defects; Recommend effective contraception for females during therapy and for seven months after treatment; present in semen; No sperm donation during and three months post-treatment	Aucun	G3 (NIOSH)	
voriconazole	Group 3-reproductive effects	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
warfarin	Group 3-reproductive effects	FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	
ziprasidone hcl	Group 3-reproductive effects	Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD; FDA Pregnancy Category C*	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)	G3 (NIOSH)	
ziv-aflibercept (M)	Absent	Absent	Absent	Absent	Notice 2015-11-05 "Pregnancy category C, package insert, table 1 proposed" Précision sous-comité : puisqu'il s'agit d'un isomère de l'aflibercept, il a été classé G3.	G3 (sous-comité)	2024-03-12
zoledronic acid	Group 3-reproductive effects	Number of stillbirths increased and survival of neonates decreased in laboratory studies at low doses; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Aucun	G3 (NIOSH)	


Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH				Sous-comité		
	Liste NIOSH 2016	Précisions NIOSH 2016	Liste NIOSH 2020	Précisions NIOSH 2020	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
zonisamide	Group 3-reproductive effects	Teratogenic in multiple miscellaneous animal species; FDA Pregnancy Category D	Table 2-reproductive hazard	Only met the NIOSH criteria as a developmental and/or reproductive hazard	Fitting criteria 2006 (pregnancy category C, organ tox, geno tox)	G3 (NIOSH)	

Légende : FDA : Food and Drug Administration, IARC : International Agency for Research on Cancer, MSHG : manufacturer safe handling guidelines, MSHI : manufacturer's safe handling instructions, NIOSH : National Institute for Occupational Safety and Health, NTP : National Toxicology Program

 : indique qu'il s'agit d'un ajout par rapport à la liste précédente. Code couleur : « G1 », « G2 » et « G3 »

Médicaments non ajoutés à la liste

Ce tableau contient les médicaments qui n'ont pas été ajoutés à la liste :

- Soit car ils ont fait l'objet d'une notice publiée par le NIOSH qui confirme qu'ils ne rencontrent pas leurs critères.
- Soit car ils ont fait l'objet d'une notice publiée par le NIOSH, mais qu'ils n'ont pas été inclus dans la publication officielle de la liste du NIOSH subséquente.
- Soit car ils ont été évalués par le sous-comité, et que celui-ci a conclu qu'il ne rencontrait pas la définition de médicament dangereux conformément à la démarche publiée du NIOSH.

Médicament	NIOSH Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
		Groupe	Date d'évaluation
abatacept	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (pregnancy category C)	Non ajouté (NIOSH notice)	2022-07-14
acamprostate calcium	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
aclidinium	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
adalimumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006	Non ajouté (NIOSH notice)	2022-07-14
adenosine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
aglucosidase	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]"	Non ajouté (NIOSH notice)	2022-07-14
albiglutide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
alcaftadine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
aldesleukine (interleukine-2)	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
alectinib	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018	Non ajouté (NIOSH notice)	2022-07-14
alefacept	Fitting criteria 2006 (cancer, pregnancy category B, organ tox)	Non ajouté (NIOSH notice)	2022-07-14
alemtuzumab	Removed in 2012 list because not meeting criteria for a hazardous drug	Non ajouté (NIOSH retrait)	2022-07-14
alendronate	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)	Non ajouté (NIOSH notice)	2022-07-14
alglucosidase	Fitting criteria 2006 (cancer not tested, pregnancy category C, organ tox, geno tox not tested) + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)	Non ajouté (NIOSH notice)	2022-07-14
alirocumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
almotriptan	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
alogliptin	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)	Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
amiodarone	Fitting criteria 2006 (cancer, pregnancy category D, repro tox, organ tox)		Non ajouté (NIOSH notice)	2022-07-14
amphetamines	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
anagrelide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
Anidulafungin	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
apixaban	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
apremilast	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
aprotinin	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
aripiprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)		Non ajouté (NIOSH notice)	2022-07-14
asenapine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
asparaginase	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs".		Non ajouté (NIOSH notice)	2022-07-14
atezolizumab	Aucun		Non ajouté (sous-comité)	2022-10-04
atomoxetine	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
avanafil	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
avelumab	Aucun		Non ajouté (sous-comité)	2022-09-13
baclofen	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
beclomethasone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
bedaquiline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
belimumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
benazepril	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
betamethasone	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
bevacizumab	Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity and teratogenicity) + Commentaires 2018 (reproductive toxicity and teratogenicity or other developmental toxicity) + Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox, organ tox)		Non ajouté (NIOSH notice)	2022-07-14
bimatoprost	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
binimetinib (†)	Aucun		Non ajouté (sous-comité)	2024-02-13
boceprevir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
botulinum toxins	Commentaires 2018 (organ toxicity at low doses and teratogenicity or other developmental toxicity) + Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (organ toxicity at low doses and teratogenicity or other developmental toxicity)		Non ajouté (NIOSH notice)	2022-07-14
brexpiprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
brolocizumab	Aucun		Non ajouté (sous-comité)	2023-02-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
bupivacaine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
buprenorphine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
bupropion	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
calcipotriene	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
calcitonin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
canagliflozin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
canakinumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
cangrelor	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
captopril	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
carbidopa	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
cariprazine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
caspofungin acetate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
cefepime	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
cefoperazone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ceftazidime/avibactam	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ceftriaxone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
cemiplimab	Aucun		Non ajouté (sous-comité)	2023-02-14
cetuximab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug) + Fitting criteria 2006 (cancer not tested, pregnancy category C, repto tox, organ tox)		Non ajouté (NIOSH notice)	2022-07-14
cholic acid	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
cinacalcet	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
citalopram	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
clarithromycin	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
clindamycine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux


Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
clomipramine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
clozapine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
collagenase clostridium histolytica	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
crisantaspase	Aucun		Non ajouté (sous-comité)	2023-03-14
dabigatran	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
daclastavir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dalbavancin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dalteparin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dapagliflozin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dapsone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
daptomycine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
daratumumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]" + Notice 2020-09332 "no proposing to place it on the list"		Non ajouté (NIOSH notice)	2022-07-14
darbepoietin alfa	Commentaires 2018 (carcinogenicity) + Notice 2020-09332 "no proposing to place it on the list" + Not fitting criteria 2006 + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (carcinogenicity)		Non ajouté (NIOSH notice)	2022-07-14
darifenacin	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
darunavir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
deferasirox	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
denileukine	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"		Non ajouté (NIOSH retrait)	2022-07-14
denosumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
deoxycholic acid	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
desipramine	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
destroamphetamine	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
desvenlafaxine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dexamethasone	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
dexlansoprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
dexmethylphenidate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
diazoxide	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux


Version du 13 mars 2024

Médicament	NIOSH Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
		Groupe	Date d'évaluation
diclofenac	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
didanosine	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
diltiazem	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
dimethyl fumarate	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
Dimethylsulfoxyde (DMSO) 	Aucun	Non ajouté (sous-comité)	2023-12-12
dinutuximab	Notice 2020-09332 "no proposing to place it on the list" = Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"	Non ajouté (NIOSH notice)	2022-07-14
dolasetron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
doripenem	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
doxazosin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
doxepin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
doxycycline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
droxidopa	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
dulaglutide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
duloxetine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
durvalumab	Aucun	Non ajouté (sous-comité)	2022-11-08
edoxaban	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
efalizumab	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
efavirenz	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (pregnancy category D)	Non ajouté (NIOSH notice)	2022-07-14
efinaconazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
eliglustat	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
elosulfase	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"	Non ajouté (NIOSH notice)	2022-07-14
elotuzumab	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)	Non ajouté (NIOSH notice)	2022-07-14
eltrombopag	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
eluxadoline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
empagliflozin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
epoetin alfa	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
escitalopram	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
esomeprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
estrone	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"		Non ajouté (NIOSH retrait)	2022-07-14
eszopiclone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)		Non ajouté (NIOSH notice)	2022-07-14
ethosuximide	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
etidronate	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
evolocumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
fentanyl	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ferumoxytol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
filgrastim	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
finafloxacin	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
flibanserin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
fluoxetine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
fluvoxamine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
fondaparinux	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
fosamprenavir	Notice 2020-09332 "no proposing to place it on the list"		Non ajouté (NIOSH notice)	2022-07-14
gabapentin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
gadobenate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
gadopentetate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
galantamine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
galsulfase	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
gefitinib	Notice 2020-09332 "no proposing to place it on the list" but scheduled to be reviewed again		Non ajouté (NIOSH notice)	2022-07-14
gemfibrozil	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
glofitamab 	Aucun		Non ajouté (sous-comité)	2024-02-13
golimumab	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
granisetron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
hyaluronidase	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
hydrocodone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
hydrocortisone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
hydromorphone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
ibandronate	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
idelalisib	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
idursulfate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
iloprost	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
imipramine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
inderal	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
infliximab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
ingenol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
insulin degludec	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
insulin detemir	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
insulin glargine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
insulin glulisine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
interferon alfa-2a	Removed in 2012 list because not meeting criteria for a hazardous drug		Non ajouté (NIOSH retrait)	2022-07-14
interferon alfa-2b	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Removed in 2012 list because not meeting criteria for a hazardous drug.		Non ajouté (NIOSH notice)	2022-07-14
interferon alfa-n3	Removed in 2012 list because not meeting criteria for a hazardous drug		Non ajouté (NIOSH retrait)	2022-07-14
interferon beta-1a	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
interferon beta-1b	Commentaires 2018 (reproductive toxicity) + Notice 2020-09332 "no proposing to place it on the list" + Not fitting criteria 2006 + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (reproductive toxicity)		Non ajouté (NIOSH notice)	2022-07-14
interferon gamma-1b	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ipilimumab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
isatuximab	Aucun		Non ajouté (sous-comité)	2022-11-22
isavuconazonium	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
itraconazole	Notice 2020-09332 "do not meet definition, dev tox observed in doses greater than the max human recommended dose" + Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
		Groupe	Date d'évaluation
ivacaftor	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
ivermectin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
ketoconazole	Notice 2020-09332 "do not meet definition, dev tox observed in doses greater than the max human 42ecommended dose" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
kunecathechin	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
lamivudine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lamotrigine	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 + Not fitting criteria 2006	Non ajouté (NIOSH notice)	2022-07-14
lanreotide	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)	Non ajouté (NIOSH notice)	2022-07-14
lansoprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lansoprazole/naproxen	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
lanthanum carbonate hydrate	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
lapatinib	Notice 2020-09332 "no proposing to place it on the list"	Non ajouté (NIOSH notice)	2022-07-14
ledipasvir/Sofosbuvir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lesinurad	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
levetiracetam	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
levomilnacipran	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
l-glutamine	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
linaclotide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2023-09-11
linagliptin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lincomycin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lisinopril	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
losartan	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lovastatin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
lubiprostone	Fitting criteria 2006 (cancer, pregnancy category C)	Non ajouté (NIOSH notice)	2022-07-14
lumacaftor/ivacaftor	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
maraviroc	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
mecasermin	Fitting criteria 2006 (cancer, pregnancy category C)	Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
mecasermin rinfabate	Not Fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
mepolizumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
methadone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
methoxy polyethylene glycol epoietin beta	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
methylphenidate	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
methylprednisolone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
metreleptin	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
micafungine sodium	Fitting criteria 2006 (cancer not tested, pregnancy category C, organ tox)		Non ajouté (NIOSH notice)	2022-07-14
milnacipran	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018		Non ajouté (NIOSH notice)	2022-07-14
minocycline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
mirabegron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
mirtazapine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
morphine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
moxifloxacin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
nabilone	Aucun		Non ajouté (sous-comité)	2022-11-08
naloxegol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
natalizumab	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (pregnancy category C, repro tox)		Non ajouté (NIOSH notice)	2022-07-14
necitumumab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
nefazodone	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
nepafenac	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
netupitant/palonosetron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
nilutamide	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"		Non ajouté (NIOSH retrait)	2022-07-14
nintedanib	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
nivolumab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
nortriptyline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
obinutuzumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
olanzapine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
olodaterol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
omalizumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
omega-3-acide ethyesters	not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
omeprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ondansetron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
oritavancin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
osimertinib	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (teratogenicity or other developmental toxicity) + Commentaires 2018 (teratogenicity or other developmental toxicity)		Non ajouté (NIOSH notice)	2022-07-14
ovine hyaluronidase	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
oxybutynin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
oxycodone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
oxymorphone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
palbociclib	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
paliperidone	Notice 10JAN2019"NIOSH has determined it is unlikely that paliperidone (Invega®) poses a carcinogenic, reproductive or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH." + Removed in 2020 draft list because "NIOSH reviewed data from studies provided by the manufacturer and determined it is unlikely that paliperidone poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH."		Non ajouté (NIOSH retrait)	2022-07-14
palonosetron	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
panitumumab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
pantoprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
paricalcitol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
pegaptanib sodium	Absent		Non ajouté (NIOSH notice)	2023-06-12
pegaspargase	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]" + Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs".		Non ajouté (NIOSH notice)	2022-07-14
pegfilgrastim	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
peginterferon alpha-2A	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
peginterferon alpha-2B	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
peginterferon beta-1A	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
		Groupe	Date d'évaluation
pembrolizumab	Notice 2020-09332 "no proposing to place it on the list but this drug is scheduled to be reviewed for the update after the 2020 List update" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
pentamidine isethionate	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
pentetate zinc trisodium	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
pentosan polysulfate na	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
peramivir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
perampanel	Notice 2015-11-05 "Pregnancy category C, package insert, table 3 proposed"	Non ajouté (NIOSH notice)	2022-07-14
pertuzumab	Removed in 2020 draft list because "NIOSH reviewed data concerning the developmental effects related to pertuzumab treatment and has determined that it is unlikely that pertuzumab poses a reproductive threat to workers in healthcare settings and is no longer considered a hazardous drug by NIOSH."	Non ajouté (NIOSH retrait)	2022-07-14
pimecrolimus	Fitting criteria 2006 (cancer, pregnancy category C, repro tox)	Non ajouté (NIOSH notice)	2022-07-14
pioglitazone	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
pioglitazone / metformin	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
pirfenidone	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018	Non ajouté (NIOSH notice)	2022-07-14
podofilox	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
podophyllum resin	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
porfimer sodique	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox, organ tox, geno tox)	Non ajouté (NIOSH notice)	2022-07-14
posaconazole	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-05-10
pramlintide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006	Non ajouté (NIOSH notice)	2022-07-14
prazosin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
pregabalin	Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox, geno tox)	Non ajouté (NIOSH notice)	2022-07-14
protriptyline	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"	Non ajouté (NIOSH notice)	2022-07-14
quetiapine fumerate	Fitting criteria 2006 (cancer, pregnancy category C, repro tox)	Non ajouté (NIOSH notice)	2022-07-14
rabeprazole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
ramelteon	Fitting criteria 2006 (cancer, pregnancy category C, repro tox, geno tox)	Non ajouté (NIOSH notice)	2022-07-14
ramipril	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
ramucirumab	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (cancer, pregnancy category C, geno tox)	Non ajouté (NIOSH notice)	2022-10-04
ranibizumab	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
ranolazine	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
regadenosone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
remdesivir	Aucun	Non ajouté (sous-comité)	2023-11-14
rifaximin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006	Non ajouté (NIOSH notice)	2022-07-14
rilpivirine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
risedronate	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
risperidone	Notice 10JAN2019 "NIOSH has determined it is unlikely that paliperidone (Invega®) poses a carcinogenic, reproductive or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH." + Fitting criteria 2006 (cancer, pregnancy category C, repro tox, organ tox) + Removed in 2020 draft list because "NIOSH reviewed data from studies provided by the manufacturer and determined it is unlikely that risperidone poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH."		Non ajouté (NIOSH retrait)	2022-07-14
rituximab	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox not tested, organ tox, geno tox not tested)		Non ajouté (NIOSH notice)	2022-07-14
rivaroxaban	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
rivastigmine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
rocuronium	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
rolapitant	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ropinirole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
rosiglitazone maleate / glimepiride	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
rotigotine	Notice 2015-11-05 "Pregnancy category C, package insert, table 3 proposed"		Non ajouté (NIOSH notice)	2022-07-14
rufinamide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
ruxolitinib	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
sacubitril/valsartan	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
samarium 153	Fitting criteria 2006 (cancer, pregnancy category D, repro tox not tested)		Non ajouté (NIOSH notice)	2022-07-14
sapropterin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
saquinavir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
saquinavir mesylate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
saxagliptin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sebelipase alfa	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
secretine humaine synthétique (ChiRhoStim)	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
secukinumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14
selegiline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
selexipag	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sertraline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sildenafil	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
siltuximab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

Médicament	NIOSH		Sous-comité	
	Notice NIOSH (publiées entre 2006 et 13-09-2023)		Groupe	Date d'évaluation
simeprevir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
simvastatin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sitagliptin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
sofosbuvir	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
solifenacin succinate	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
somatropin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sotorasib (†)	Aucun		Non ajouté (sous-comité)	2024-03-12
strontium-89 chloride	Fitting criteria 2006 (cancer, pregnancy category D, repro tox not tested, geno tox not tested)		Non ajouté (NIOSH notice)	2022-07-14
sugammadex	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sulfasalazine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
sulfur hexafluoride lipid type-A	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
suvorexant	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tadalafil	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tafasitamab (†)	Aucun		Non ajouté (sous-comité)	2024-02-13
taliglucerase	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tamsulosin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tapentadol	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tasimelteon	Notice 2018-02957 "Available toxicity information does not demonstrate or support a determination that the drug meets the niosh definition of a hazardous drug [category 4]" + Commentaires 2018 (this drug does not meet the NIOSH definition of a hazardous drug)		Non ajouté (NIOSH notice)	2022-07-14
tavaborole	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tebentafusp	Aucun		Non ajouté (sous-comité)	2023-05-09
tedizolide	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
telavancin	Notice 12APR2017 "NIOSH has determined that telavancin (VIBATIV®) does not meet the NIOSH definition of a hazardous drug and is no longer considered a hazardous drug by NIOSH." + Removed in 2020 draft list because "Telavancin was removed from the NIOSH list based on data from reproductive studies provided by the manufacturer concerning its lack of reproductive toxicity."		Non ajouté (NIOSH retrait)	2022-07-14
telbivudine	Not fitting criteria 2006		Non ajouté (NIOSH notice)	2023-06-12
telithromycin	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Not fitting criteria 2006		Non ajouté (NIOSH notice)	2022-07-14
telmisartan	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"		Non ajouté (NIOSH notice)	2022-07-14
tenofovir	Fitting criteria 2006 (cancer, pregnancy category B, repro tox, organ tox, geno tox)		Non ajouté (NIOSH notice)	2022-07-14

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024


Médicament	NIOSH Notice NIOSH (publiées entre 2006 et 13-09-2023)	Sous-comité	
		Groupe	Date d'évaluation
testolactone	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
tetracycline HCL	Removed in 2014 list "on the basis of stakeholder comments"	Non ajouté (NIOSH retrait)	2022-07-14
tiagabine	Not fitting 2006	Non ajouté (NIOSH notice)	2023-06-12
ticagrelor	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
tigecycline	Fitting criteria 2006 (cancer not tested, pregnancy category D)	Non ajouté (NIOSH notice)	2022-07-14
tinidazole	Fitting criteria 2006 (cancer not tested, pregnancy category C, repro tox)	Non ajouté (NIOSH notice)	2022-07-14
tiotropium bromide	Fitting criteria 2006 (pregnancy category C, repro tox)	Non ajouté (NIOSH notice)	2022-07-14
tipranavir	Not fitting 2006	Non ajouté (NIOSH notice)	2023-06-12
tolvaptan	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
trastuzumab	Commentaires 2018 (organ toxicity at low doses and teratogenicity or other developmental toxicity) + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (organ toxicity at low doses and teratogenicity or other + Not fitting criteria 2006	Non ajouté (NIOSH notice)	2022-07-14
trazodone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
triamcinolone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
triazolam	Notice 2020-09332 "no proposing to place it on the list" + Notice 2018-02957 "Drug proposed for placement on the list category 1 & 5" (mimics existing drugs determined hazardous by exhibiting teratogenicity or other developmental toxicity) + Commentaire 2018 (mimics existing drugs determined hazardous by exhibiting teratogenicity or other developmental toxicity)	Non ajouté (NIOSH notice)	2022-11-08
trifluridine (seul, pas la combinaison)	Removed in 2014 list for "not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH notice)	2023-11-14
trimipramine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
tropium chloride	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
trypan blue	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (cancer, pregnancy category C, geno tox)	Non ajouté (NIOSH notice)	2022-07-14
uridine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
valsartan	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
vardeafil	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
varenicline	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]" + Fitting criteria 2006 (pregnancy category C)	Non ajouté (NIOSH notice)	2022-07-14
vedolizumab	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"	Non ajouté (NIOSH notice)	2022-07-14
velaglucerase	Notice 2018-02957 "Insufficient toxicity information available to meet niosh definition of hazardous drug [category 2]"	Non ajouté (NIOSH notice)	2022-07-14
venlafaxine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
verteporfin	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12
vidarabine	Removed in 2014 list "for not meeting the NIOSH criteria for hazardous drugs"	Non ajouté (NIOSH retrait)	2022-07-14
vilazodone	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
vorapaxar	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
vortioxetine	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14
ziconotide	Not fitting criteria 2006	Non ajouté (NIOSH notice)	2023-06-12

Liste de médicaments dangereux

Communauté de pratique du Québec pour la manipulation sécuritaire des médicaments dangereux

Version du 13 mars 2024

NIOSH		Sous-comité	
Médicament	Notice NIOSH (publiées entre 2006 et 13-09-2023)	Groupe	Date d'évaluation
zolpidem	Notice 2018-02957 "Available information shows a toxic effect that does not meet the niosh definition of hazardous drug [category 3]"	Non ajouté (NIOSH notice)	2022-07-14

Légende  : indique qu'il s'agit d'un ajout par rapport à la liste précédente

Médicaments non évalués ou exclus

Ce tableau contient les médicaments qui n'ont pas été évalués par le sous-comité :

- Soit qui n'ont pas fait l'objet ni d'une liste ni d'une notice publiée par le NIOSH.
- Soit qu'ils seront évalués prochainement par le sous-comité.
- Soit qu'ils ont été exclus de la portée des travaux (p.ex. non commercialisés au Canada, encadré par des normes pour agents radio-actifs, ou en matière de biosécurité).

Médicaments à évaluer par le sous-comité

Médicament	Sous-comité
amivantamab	Non-évalué
avacopan	Non-évalué
belzutifan	Non-évalué
calaspargase pegol (M)	Non-évalué
carbetocin	Non-évalué
carboprost	Non-évalué
cenobamate	Non-évalué
dexmedetomidine	Non-évalué
dienestrol	Non-évalué
dolutegravir	Non-évalué
dostarlimab (M)	Non-évalué
eflornithine hydrochloride (DFMO)	Non-évalué
elranatamab (M)	Non-évalué
énasidénib	Non-évalué
entrectinib	Non-évalué
epcoritamab (M)	Non-évalué
erdafitinib	Non-évalué
foscarnet (M)	Non-évalué
giltéritinib	Non-évalué
glasdégib	Non-évalué
inebilizumab (M)	Non-évalué
levonorgestrel	Non-évalué
luspatercept	Non-évalué
mavacamtem	Non-évalué
mogamulizumab	Non-évalué
norethindrone	Non-évalué
ofatumumab	Non-évalué
phentolamine	Non-évalué

phénylbutyrate de sodium et ursodoxicoltaurine	Non-évalué
ripretinib	Non-évalué
selinexor	Non-évalué
selpercatinib	Non-évalué
selumetinib	Non-évalué
siponimod	Non-évalué
téclistamab	Non-évalué
THC-CBD	Non-évalué
tositumomab	Non-évalué
tremelimumab (M)	Non-évalué
zalcitabine	Non-évalué

Légende (M) : indique qu'il s'agit d'un ajout par rapport à la liste précédente

Médicaments exclus qui ne seront pas évalués par le sous-comité

Médicament	Sous-comité
amifostine	Exclu
axicabtagène ciloleucel	Exclu
brexucabgagène autoleucel	Exclu
brincidofovir	Exclu
ciltacabtagène autoleucel	Exclu
dacomitinib	Exclu
edavarone	Exclu
flucytosine	Exclu
guadecitabine	Exclu
ibritumomab tiuxetan	Exclu
imetelstat	Exclu

infigratinib	Exclu
interferon alfa-n1	Exclu
ivosidénib	Exclu
lisocabtagène maraleucel	Exclu
lonafarnib	Exclu
lutécium vipivotide tétraxétan	Exclu
navitoclax	Exclu
nicotine	Exclu
olaratumab	Exclu
onasemnogene abeparvec	Exclu
oxandrolone	Exclu
pacritinib	Exclu
perphosphamide	Exclu
piritrexim isethionate	Exclu
pirtobrutinib	Exclu
plicamycin	Exclu
pralseltinib	Exclu
prednimustine	Exclu
quinagolide	Exclu
rizalbrutinib	Exclu
tagraxofusp	Exclu
talimogene laherparepvec	Exclu
tovorafenib	Exclu
trimetrexate glucuronate (trimetrexate)	Exclu
vindesine	Exclu
voretigene neparvec	Exclu

Légende (M) : indique qu'il s'agit d'un ajout par rapport à la liste précédente

Suivi des changements à la liste de médicaments dangereux

Ce tableau résume les changements à la liste. Les nouvelles classifications sont également identifiées par (*) directement dans les tableaux.

Version	Changements
Version 20231117	Version originale.
Publiée le 4 décembre 2023	
Version 20240312	<p>Nouveaux médicaments du groupe « G1 »</p> <ul style="list-style-type: none"> - Décitabine-cédazuridine - Hydrate de chloral <hr/> <p>Nouveaux médicaments du groupe « G2 »</p> <ul style="list-style-type: none"> - Aucun <hr/> <p>Nouveaux médicaments du groupe « G3 »</p> <ul style="list-style-type: none"> - Danazol - Fedratinib - Lorlatinib - Nélatinib - Pemigatinib - Tucatinib <hr/> <p>Nouveaux médicaments ajoutés à la liste « non-ajoutés »</p> <ul style="list-style-type: none"> - Binimétinib - Diméthylsulfoxyde (DMSO) - Glofitamab - Sotorasib - Tafasitamab <hr/> <p>Nouveaux médicaments ajoutés à la liste « exclus »</p> <ul style="list-style-type: none"> - Aucun <hr/> <p>Nouveaux médicaments ajoutés à la liste « non évalués »</p> <ul style="list-style-type: none"> - Calaspargase pegol - Dostarlimab - Elranatamab - Epcoritamab - Foscarnet - Inebilizumab - Trémélimumab <hr/> <p>Corrections</p> <ul style="list-style-type: none"> - Correction du doublon d'affibercept - Correction de l'orthographe du binimétinib - Correction de l'orthographe du dostarlimab